ReviewBioMed research international2018
Recent Advances in HBV Reactivation Research.
Review in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- HBV reactivation in HCC patients following TACE: risk factors, antiviral therapy impact, and survival analysis.Frontiers in oncology · 2026Article
- HBV reactivation during immunotherapy for hepatocellular carcinoma: risk factors and clinical management.Frontiers in immunology · 2026Review
- The interplay between hepatitis B virus and antitumor drugs in the treatment of hepatocellular carcinoma.Clinical and experimental medicine · 2025Review
- Risk of hepatic decompensation from hepatitis B virus reactivation in hematological malignancy treatments.World journal of gastroenterology · 2024Article
- Effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome.NPJ vaccines · 2023Article
- Multi-omic analysis of glycolytic signatures: exploring the predictive significance of heterogeneity and stemness in immunotherapy response and outcomes in hepatocellular carcinoma.Frontiers in molecular biosciences · 2023Article
- Direct-Acting Antivirals and the Risk of Hepatitis B Reactivation in Hepatitis B and C Co-Infected Patients: A Systematic Review and Meta-Analysis.Journal of personalized medicine · 2022Review
- COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature.Pathogens (Basel, Switzerland) · 2022Review
- [Drugs and hepatitis B virus reactivation].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2022Article
- Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection.Internal and emergency medicine · 2022Article
- Hepatitis B virus reactivation in rheumatoid arthritis.World journal of clinical cases · 2022Review
- Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review.Journal of Cancer · 2022Review
- SARS-CoV-2: lessons from both the history of medicine and from the biological behavior of other well-known viruses.Future microbiology · 2021Review
- Frequency of Hepatitis B Virus infection among Patients before Chemotherapy Treatment.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study.Translational lung cancer research · 2021Article
- [Consensus of Chinese experts on prevention and standardized treatment of drug-induced liver injury in patients with blood diseases (2021)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger?World journal of gastroenterology · 2020Review
- Effects of Antiviral Therapy on HBV Reactivation and Survival in Hepatocellular Carcinoma Patients Undergoing Hepatic Artery Infusion Chemotherapy.Frontiers in oncology · 2020Article
- Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention.World journal of gastroenterology · 2019Review
- Hepatitis B Virus Reactivation Following Treatment of HNSCC With Cisplatin.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) is an important public health problem that poses a serious threat to human health. HBV reactivation generally occurs in overt or occult HBV infection patients who suffered DDAs, chemotherapy, or immunosuppressive therapy, especially when some solid tumors and leukemia patients are using hormones such as prednisolone and imatinib. The approximate incidence of HBV reactivation ranged from about 10% to 40%. Scientists often explore the molecular mechanisms from both the virus and the host. But some studies have reported that some drugs (cisplatin, rituximab, imatinib, and glucocorticoid) could induce HBV reactivation directly. However, the specific molecular mechanisms were unclear. With the emergence of new antiviral drugs and molecular targeted drugs, the risk of HBV reactivation will increase significantly. Therefore this review was expected to be used to provide recommendations for future research in HBV reactivation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.